Level C· Early human research exploring benefitsRetrospective StudyPubMed

Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation.

Barajas Ordonez F., Wolleschak D., Zeller Y., Hinnerichs M., Rodríguez-Feria P., Aghayev A.

Retrospective Study with a reported sample of 129 on Scar, published in Leuk Lymphoma (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Leuk Lymphoma (2024)
Country
United States
Reported sample size
129
Source database
PubMed
PMID
38384127
DOI
10.1080/10428194.2024.2319226

Abstract (original English)

Studies regarding the influence of body composition parameters as predictors on overall survival (OS) in patients with multiple myeloma (MM) are scarce. OS and progression-free survival (PFS) were retrospectively assessed in 129 patients with MM undergoing autologous stem cell transplantation (ASCT) after a follow-up of 2 years. A computed tomography (CT) based semi-automated assessment of body composition was performed. No statistically significant differences were noted in 2-year OS, PFS, or post-transplant adverse events in the body composition groups of subcutaneous adipose tissue (SAT) (low vs. high-SAT), visceral adipose tissue (VAT) (low vs. high-VAT), visceral-to-subcutaneous fat ratio (VSR) (low vs. high VSR), and sarcopenia in terms of skeletal muscle index (SMI) (non-sarcopenic vs. sarcopenic). In conclusion, adipose and muscle tissue do not limit OS or affect the PFS in patients with MM undergoing ASCT.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansMultiple MyelomaBody CompositionMaleFemaleTransplantation, AutologousMiddle AgedAgedHematopoietic Stem Cell TransplantationRetrospective Studies

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research